Bone Disease and Liver Transplantation: A Review.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 01 03 2021
accepted: 23 07 2021
pubmed: 24 8 2021
medline: 26 11 2021
entrez: 23 8 2021
Statut: ppublish

Résumé

Liver transplantation is currently the most effective and almost routine treatment for chronic and acute liver diseases. The survival of transplanted patients has increased exponentially, which has led to more knowledge of the long-term complications secondary to the underlying pathology or the various treatments that must be followed. Bone metabolic disease is a chronic complication of liver transplantation that inhibits quality of life. The factors that contribute to the development of bone disease are different according to the various etiologies of liver damage. All patients should be examined for osteoporosis risk factors because the incidence of new fractures in transplant patients is higher during the first year after transplantation, reflecting the greater bone loss during this time. This article outlines a proposal for a treatment algorithm; we propose that pharmacologic therapy in patients post liver transplant should first consider the diagnosis of osteoporosis by bone mineral density, the patient's personal and family history of spine and femoral neck fractures, and the use glucocorticoids (dose and time) until a tool is available that allows the best estimation of the fracture risk in this population of patients.

Identifiants

pubmed: 34420781
pii: S0041-1345(21)00530-3
doi: 10.1016/j.transproceed.2021.07.049
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2346-2353

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Erika Faride Rodríguez-Aguilar (EF)

Liver Transplant Unit, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (Ciberhed), Barcelona, Spain.

Juanita Pérez-Escobar (J)

Gastroenterology and Hepatology, Punto Clínico Especialistas, México City, Mexico.

Diana Sánchez Herrera (D)

Facultad Mexicana de Medicina, Universidad La Salle, Hospital Ángeles Pedregal, México City, Mexico.

Mario García-Alanis (M)

Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico.

Liz Toapanta-Yanchapaxi (L)

Clínica de Enfermedades Neuromusculares, Departamento de Neurología y Psiquiatría, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico.

Eduardo Gonzalez-Flores (E)

Centro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), México City, Mexico.

Ignacio García-Juárez (I)

Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico. Electronic address: drinter77@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH